There’s a new option to help patients with chronic pain. NeuraLace Medical has received FDA clearance for its Axon Therapy, a technology that non-invasively stimulates peripheral nerves and provides chronic nerve pain relief.
The San Diego, CA-based company said its technology delivers focused magnetic pulses which activate the damaged peripheral nerve axons that are required to provide relief from chronic nerve pain.
The Axon Therapy coil, connected to a compact stimulation module, produces strong magnetic pulses near the injured nerve during the course of the treatment. NeuraLace's low-frequency waveform leverages the principles of electromagnetic induction to create a voltage differential that elicits neuronal stimulation in the axon of the damaged nerve resulting in pain relief.
“After 10 years of R&D, we are pleased to have received FDA 510(k) clearance for Axon Therapy and we're incredibly excited to bring to market a non-opioid treatment option that provides meaningful relief for patients suffering from chronic pain,” said Shiv Shukla, Founder, and CEO of NeuraLace Medical. “We believe Axon Therapy is a significant step forward on the care continuum that is accessible to patients today and we look forward to bringing sustainable pain relief to patients by launching Axon Therapy in the U.S.”